Here’s what you should know:
1. The company is enrolling 12 to 15 patients into the open-label trial. It expects to report data from the first six patients by September 2017.
2. The company said enrollment has been slower than expected. To alleviate that, AzurRx added an additional site in Australia.
3. The company reported data from the first three patients in the second quarter of fiscal year 2017. In those patients, the drug caused a 20 percent improvement in coefficient of fat absorption at the second or third escalating dose level.
4. MS1819 also touted a favorable safety profile, with no moderate or severe adverse events reported.
More articles on gastroenterology:
Florida jury finds gastroenterologist not liable in alleged ‘slapdash colonoscopy’ trial — 6 insights
Contaminated scopes used in 500+ patients at Buffalo VA
Renewed interest in gastroparesis research brings cure into focus
